DK158539C - Dipyridamol-retardformer og fremgangsmaade til fremstilling heraf - Google Patents
Dipyridamol-retardformer og fremgangsmaade til fremstilling herafInfo
- Publication number
- DK158539C DK158539C DK009481A DK9481A DK158539C DK 158539 C DK158539 C DK 158539C DK 009481 A DK009481 A DK 009481A DK 9481 A DK9481 A DK 9481A DK 158539 C DK158539 C DK 158539C
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- preparing
- retard forms
- dipyridamol
- dipyridamol retard
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803000979 DE3000979A1 (de) | 1980-01-12 | 1980-01-12 | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
DE3000979 | 1980-01-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK9481A DK9481A (da) | 1981-07-13 |
DK158539B DK158539B (da) | 1990-06-05 |
DK158539C true DK158539C (da) | 1990-11-05 |
Family
ID=6091926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK009481A DK158539C (da) | 1980-01-12 | 1981-01-09 | Dipyridamol-retardformer og fremgangsmaade til fremstilling heraf |
Country Status (32)
Country | Link |
---|---|
US (1) | US4367217A (pt) |
EP (1) | EP0032562B1 (pt) |
JP (1) | JPS56103111A (pt) |
AR (1) | AR221983A1 (pt) |
AT (1) | ATE6585T1 (pt) |
AU (1) | AU539618B2 (pt) |
CA (1) | CA1148084A (pt) |
CS (1) | CS232713B2 (pt) |
DD (1) | DD156943A5 (pt) |
DE (2) | DE3000979A1 (pt) |
DK (1) | DK158539C (pt) |
ES (1) | ES8207428A1 (pt) |
FI (1) | FI78835C (pt) |
GB (1) | GB2067073B (pt) |
GR (1) | GR73102B (pt) |
HK (1) | HK62184A (pt) |
HU (1) | HU184366B (pt) |
IE (1) | IE50807B1 (pt) |
IL (1) | IL61887A (pt) |
IN (1) | IN155158B (pt) |
KE (1) | KE3402A (pt) |
MA (1) | MA19040A1 (pt) |
MY (1) | MY8500559A (pt) |
NO (1) | NO157369C (pt) |
NZ (1) | NZ195994A (pt) |
OA (1) | OA06720A (pt) |
PH (1) | PH17063A (pt) |
PL (1) | PL129290B1 (pt) |
PT (1) | PT72330B (pt) |
SG (1) | SG28184G (pt) |
YU (1) | YU42549B (pt) |
ZA (1) | ZA811661B (pt) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
ATE14379T1 (de) * | 1981-04-27 | 1985-08-15 | Haessle Ab | Pharmazeutisches praeparat. |
DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
DE3126703A1 (de) * | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
IE54171B1 (en) * | 1982-06-22 | 1989-07-05 | Univ Glasgow | Device for introducing nutrients and/or therapeutic materials into ruminant animals |
US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
DK58983D0 (da) * | 1983-02-11 | 1983-02-11 | Leo Pharm Prod Ltd | Farmaceutisk praeparat |
DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
HU191542B (en) * | 1983-04-08 | 1987-03-30 | Boehringer Ingelheim Ltd | Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance |
JPS6051106A (ja) * | 1983-08-31 | 1985-03-22 | Yamanouchi Pharmaceut Co Ltd | 塩酸アモスラロ−ル持続性製剤 |
IE56459B1 (en) * | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
GB8414220D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
GB8414221D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Unit dosage form |
US4867984A (en) * | 1984-11-06 | 1989-09-19 | Nagin K. Patel | Drug in bead form and process for preparing same |
DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
WO1988002629A1 (en) * | 1986-10-16 | 1988-04-21 | American Health Products Corporation | 2',3'-didesoxyadenosine composition |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
IL84599A0 (en) * | 1986-12-09 | 1988-04-29 | Byk Gulden Lomberg Chem Fab | Pharmaceutical composition containing urapidil and process for the preparation thereof |
DE3812799A1 (de) * | 1988-04-16 | 1989-10-26 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung |
GB8813032D0 (en) * | 1988-06-02 | 1988-07-06 | Boehringer Ingelheim Int | Antiviral pharmaceutical composition |
US5196203A (en) * | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
AT397345B (de) * | 1990-04-04 | 1994-03-25 | Chemiefaser Lenzing Ag | Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen |
EP0585355B1 (en) * | 1991-05-20 | 1995-03-22 | Marion Laboratories, Inc. | Multi-layered controlled release formulation |
ES2173096T3 (es) * | 1992-08-05 | 2002-10-16 | Faulding F H & Co Ltd | Composicion farmaceutica peletizada. |
US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
US20060263428A1 (en) * | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
US20060067999A1 (en) * | 1996-03-25 | 2006-03-30 | Wyeth | Extended release formulation |
JP2000159692A (ja) * | 1998-09-25 | 2000-06-13 | Sankyo Co Ltd | HMG―CoAレダクタ―ゼ阻害薬含有製剤 |
WO2000018396A1 (fr) * | 1998-09-25 | 2000-04-06 | Sankyo Company, Limited | PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA |
US6475493B1 (en) | 1999-09-02 | 2002-11-05 | Norstrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
JP2003510349A (ja) * | 1999-10-07 | 2003-03-18 | ノヴァ−ニューロン インコーポレーテッド | 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物 |
EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
PT1276470E (pt) | 2000-04-20 | 2007-08-13 | Novartis Ag | Composição de revestimento para dissimular o sabor |
US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
WO2003030823A2 (en) * | 2001-10-05 | 2003-04-17 | Combinatorx, Incorporated | Combinations for the treatment of immunoinflammatory disorders |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
EP1594503A2 (en) | 2003-02-07 | 2005-11-16 | Boehringer Ingelheim International GmbH | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
DE10306179A1 (de) | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
JP2006524203A (ja) | 2003-04-24 | 2006-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | トロンビンの過剰形成及び/又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
US20050112199A1 (en) * | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
CN101068570A (zh) * | 2004-05-13 | 2007-11-07 | 贝林格尔·英格海姆国际有限公司 | 双嘧达莫治疗血小板抑制剂的抗药性的用途 |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
US20060199805A1 (en) * | 2005-03-04 | 2006-09-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
JP2008534477A (ja) | 2005-03-22 | 2008-08-28 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク | 可溶化イブプロフェン |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
MX2008002492A (es) * | 2005-08-22 | 2008-04-03 | Novartis Ag | Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante. |
GB0517204D0 (en) * | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
US7923449B2 (en) * | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
KR20140088230A (ko) | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
CA2640460C (en) * | 2006-01-27 | 2015-05-26 | Eurand, Inc | Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids |
EP1820506B1 (en) * | 2006-02-09 | 2008-03-26 | Teva Pharmaceutical Industries Ltd. | Dipyridamole extended-release formulations and process for preparing same |
AU2007247094B2 (en) * | 2006-05-09 | 2012-11-01 | Sprout Pharmaceuticals, Inc. | Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders |
CA2652773A1 (en) * | 2006-05-22 | 2007-12-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels |
CA2654798C (en) | 2006-06-30 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
AU2007286288A1 (en) | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
EP1894561A1 (en) * | 2006-08-30 | 2008-03-05 | Dr. Reddy's Laboratories Ltd. | Dipyridamole pharmaceutical compositions |
WO2008116890A2 (en) * | 2007-03-28 | 2008-10-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
CA2737131A1 (en) * | 2007-09-19 | 2009-03-26 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
AU2008338980A1 (en) * | 2007-12-17 | 2009-06-25 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
AU2008343787B2 (en) | 2007-12-28 | 2014-01-30 | Impax Laboratories, Llc | Controlled release formulations of levodopa and uses thereof |
WO2009097156A1 (en) * | 2008-02-01 | 2009-08-06 | Barr Laboratories, Inc. | Pharmaceutical capsules comprising extended release dipyridamole pellets |
US8133506B2 (en) | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
WO2010036975A2 (en) * | 2008-09-25 | 2010-04-01 | Teva Pharmaceutical Industries Ltd. | Dipyridamole and acetylsalicylic acid formulations and process for preparing same |
AU2010234339B2 (en) * | 2009-04-09 | 2014-06-26 | Alkermes Pharma Ireland Limited | Drug delivery composition |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
EP2361615A1 (en) | 2010-02-19 | 2011-08-31 | Alfred E. Tiefenbacher GmbH & Co. KG | Dipyridamole prolonged-release tablet |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10098845B2 (en) | 2013-10-07 | 2018-10-16 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CN105640909B (zh) * | 2014-11-14 | 2019-09-20 | 正大天晴药业集团股份有限公司 | 一种含有达比加群酯的药用组合物 |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2853420A (en) * | 1956-01-25 | 1958-09-23 | Lowey Hans | Ethyl cellulose coatings for shaped medicinal preparations |
US2928770A (en) * | 1958-11-28 | 1960-03-15 | Frank M Bardani | Sustained action pill |
US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
NL297631A (pt) * | 1963-06-03 | |||
US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
DE2010416B2 (de) * | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
DE2031871C3 (de) * | 1970-06-27 | 1974-06-27 | Roehm Gmbh, 6100 Darmstadt | Überzugsmasse für Arzneiformen |
US3954959A (en) * | 1973-03-28 | 1976-05-04 | A/S Alfred Benzon | Oral drug preparations |
GB1468172A (en) * | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
DE2336218C3 (de) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
GB1479655A (en) | 1974-03-08 | 1977-07-13 | Beecham Group Ltd | Antibiotic preparations |
FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
GB1576376A (en) * | 1977-03-30 | 1980-10-08 | Benzon As Alfred | Multiple-unit drug dose |
LU77353A1 (pt) * | 1977-05-16 | 1979-01-19 | ||
DD146547A5 (de) | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
IE48715B1 (en) * | 1978-12-22 | 1985-05-01 | Elan Corp Plc | New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same |
-
1980
- 1980-01-12 DE DE19803000979 patent/DE3000979A1/de not_active Withdrawn
- 1980-12-12 IN IN896/DEL/80A patent/IN155158B/en unknown
- 1980-12-17 EP EP80107963A patent/EP0032562B1/de not_active Expired
- 1980-12-17 DE DE8080107963T patent/DE3067058D1/de not_active Expired
- 1980-12-17 AT AT80107963T patent/ATE6585T1/de active
- 1980-12-31 US US06/221,834 patent/US4367217A/en not_active Expired - Lifetime
-
1981
- 1981-01-09 GB GB8100632A patent/GB2067073B/en not_active Expired
- 1981-01-09 ES ES498393A patent/ES8207428A1/es not_active Expired
- 1981-01-09 PT PT72330A patent/PT72330B/pt unknown
- 1981-01-09 PL PL1981229157A patent/PL129290B1/pl unknown
- 1981-01-09 CA CA000368242A patent/CA1148084A/en not_active Expired
- 1981-01-09 GR GR63825A patent/GR73102B/el unknown
- 1981-01-09 YU YU39/81A patent/YU42549B/xx unknown
- 1981-01-09 IE IE40/81A patent/IE50807B1/en not_active IP Right Cessation
- 1981-01-09 DK DK009481A patent/DK158539C/da not_active IP Right Cessation
- 1981-01-09 NO NO810061A patent/NO157369C/no not_active IP Right Cessation
- 1981-01-09 IL IL61887A patent/IL61887A/xx not_active IP Right Cessation
- 1981-01-09 FI FI810058A patent/FI78835C/fi not_active IP Right Cessation
- 1981-01-09 NZ NZ195994A patent/NZ195994A/en unknown
- 1981-01-09 DD DD81226911A patent/DD156943A5/de not_active IP Right Cessation
- 1981-01-12 AR AR283919A patent/AR221983A1/es active
- 1981-01-12 MA MA19241A patent/MA19040A1/fr unknown
- 1981-01-12 OA OA57296A patent/OA06720A/xx unknown
- 1981-01-12 AU AU66156/81A patent/AU539618B2/en not_active Expired
- 1981-01-12 CS CS81232A patent/CS232713B2/cs unknown
- 1981-01-12 ZA ZA008101661A patent/ZA811661B/xx unknown
- 1981-01-12 PH PH25080A patent/PH17063A/en unknown
- 1981-01-12 HU HU8168A patent/HU184366B/hu unknown
- 1981-01-12 JP JP303881A patent/JPS56103111A/ja active Granted
-
1984
- 1984-04-04 SG SG281/84A patent/SG28184G/en unknown
- 1984-04-12 KE KE3402A patent/KE3402A/xx unknown
- 1984-08-09 HK HK621/84A patent/HK62184A/xx not_active IP Right Cessation
-
1985
- 1985-12-30 MY MY559/85A patent/MY8500559A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK158539C (da) | Dipyridamol-retardformer og fremgangsmaade til fremstilling heraf | |
DK224781A (da) | Imidazo-rifamycin-derivater og fremgangsmaade til fremstilling deraf | |
DK304781A (da) | Formdel og fremgansmaade til fremstolling heraf | |
DK493882A (da) | Faeldningskiselsyre og fremgangsmaade til fremstilling deraf | |
DK99382A (da) | Dichlorquinolinderivater og fremgangsmaade til fremstilling heraf | |
NO813142L (no) | N-arylbenzamid-derivater og fremgangsmaate for deres fremstilling. | |
DK493583D0 (da) | Azolderivater og fremgangsmade til fremstilling deraf | |
DK211382A (da) | Cephalosporinderivater og fremgangsmaade til deres fremstilling | |
DK574581A (da) | Delta2-1,2,4-triazolin-5-on-derivater og fremgangsmaade til fremstilling heraf | |
DK130182A (da) | Antagonister for argininvasopressin og fremgangsmaade til fremstilling heraf | |
DK446982A (da) | Cyanosteroider og fremgangsmaade til deres fremstilling | |
DK276683A (da) | Carbapenemer og fremgangsmaade til fremstilling deraf | |
DK157683D0 (da) | N-phosphonomethylglycinderivater og fremgangsmade til fremstilling og anvendelse deraf | |
DK567781A (da) | Phenoxyalkoxysilaner og fremgangsmaade til fremstilling heraf | |
DK572583A (da) | Pyridinderivater og fremgangsmaade til fremstilling deraf | |
DK108581A (da) | 2-penem-3-carboxylsyre-derivater og fremgangsmaade til fremstiling heraf | |
DK361982A (da) | Carbostyrilderivater og fremgangsmaade til fremstilling heraf | |
DK537481A (da) | 5-amino-1-phenyl-4-cyanpyrazoler og fremgangsmaade til fremstilling heraf | |
DK199183D0 (da) | Quinolinderivater og fremgangsmade til fremstilling deraf | |
DK401882A (da) | Cyclopentadienderivater og fremgangsmaader til deres fremstilling | |
DK251281A (da) | N6-adenosiner og fremgangsmaader til deres fremstilling | |
DK176481A (da) | Terapeutisk virksomme adenosin-derivater og fremgangsmaade til fremstilling heraf | |
DK250381A (da) | Carbostyrilderivater og fremgangsmaade til fremstilling deraf | |
DK160744C (da) | Oxychloreringskatalysator-praekursor til oxychlorering og fremgangsmaade til fremstilling heraf | |
DK271281A (da) | Haardfeldt og fremgangsmaade til fremstilling deraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUP | Patent expired |